Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | BCHE | P06276 | 3/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.63 |
| ▸ | CNR1 | P21554 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756259 | 0.95 | OPRM1 (0.70) | OPRM1BCHEACE2CNR1CNR2 | |
| SCHEMBL7850802 | 0.94 | OPRM1 (0.71) | OPRM1BCHEACE2CNR1CNR2 | |
| SCHEMBL13472463 | 0.94 | OPRM1 (0.71) | OPRM1BCHEACE2CNR1CNR2 | |
| SCHEMBL12756258 | 0.90 | BCHE (0.73) | OPRM1BCHEACE2CNR1CNR2 | |
| SCHEMBL7859647 | 0.89 | BCHE (0.79) | OPRM1BCHECNR1CNR2 | |
| SCHEMBL19472331 | 0.89 | BCHE (0.79) | OPRM1BCHECNR1CNR2 | |
| SCHEMBL16404764 | 0.88 | BCHE (0.66) | OPRM1BCHEACE2 | |
| SCHEMBL8032251 | 0.86 | OPRM1 (0.68) | OPRM1BCHEACE2CNR1CNR2 | |
| SCHEMBL12756262 | 0.86 | OPRM1 (0.68) | OPRM1BCHEACE2CNR1CNR2 | |
| SCHEMBL13472477 | 0.86 | OPRM1 (0.68) | OPRM1BCHEACE2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | OPRM1 35/4885BCHE 166/4885ACE2 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.